PressReleases
Press Releases
Kineta Press Releases
VISTA Blocking KVA12123 Monoclonal Antibody (mAb) Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse
SEATTLE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta, will present live at the Life Science Investor Forum, hosted by VirtualInvestorConferences.com, on December 14th, 2023.
SEATTLE, Nov. 28, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel
SEATTLE, Nov. 09, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel
Favorable Clinical Safety and Tolerability Profile Observed with No Evidence of CRS-associated Cytokines Achieved Greater Than Dose-Proportional Pharmacokinetics Biomarker
Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of
Lead Anti-CD27 Monoclonal Antibody Showed High Binding Affinity and Specificity Drives Strong T Cell Activation and Proliferation as well
The Combination Arm (Part B) of the Phase 1/2 Clinical Trial Builds Upon the Initial Safety, Tolerability and Pharmacokinetic
SEATTLE, Oct. 12, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies
Disclaimer: The Press Releases on this page are provided for historical purposes only. The information contained in each [press release/news article/event] is accurate only as of the date each was originally issued. Kineta disavows any obligation to update the information after the date of their issuance.